p21-activated kinase 4 (PAK4) regulates a wide range of cellular events, including cytoskeletal remodeling, cell growth, and survival. Our previous study identified PAK4 as a key regulator of
cAMP-response element-binding protein (CREB) that acts upstream of
microphthalmia-associated transcription factor (MITF), a master
transcription factor in melanogenesis. We therefore investigated the role of PAK4 in melanogenesis. Melanocytes express both PAK2 and PAK4
isoforms, but only RNA interference knockdown of PAK4 significantly influenced α-
melanocyte-stimulating hormone (α-
MSH)-induced melanogenesis in
B16 melanoma cells. Consistent with this result, PAK4 inhibition by
PF3758309, a potent
ATP-competitive inhibitor of PAKs, suppressed not only α-
MSH-induced melanogenesis in
B16 melanoma and human epithelial melanocyte cells but also UVB-induced melanogenesis in the skin of
melanin-possessing hairless mice (HRM-2) in a dose-dependent manner. Inhibition of PAK4 over several days markedly decreased the levels of CREB, MITF, and
tyrosinase in both HRM-2 mice and
B16 melanoma cells. Moreover, PAK4 knockdown and inhibition suppressed α-
MSH-stimulated β-
catenin phosphorylation at
serine 675 (S675) but enhanced phosphorylation at S33/37, an
indicator for ubiquitination-dependent proteolysis. Together, our results provide evidence that PAK4 promotes α-
MSH/UVB-induced melanogenesis via the CREB and Wnt/β-
catenin signaling pathways and suggest that PAK4 may be a potential therapeutic target in
pigmentation disorders.